VXRT Vaxart Covid-19, Uptrend and Price Target
VXA-CoV2-1, Vaxart's experimental treatment for Covid-19 is unique in that it's a pill, not an injection.
A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates.
On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies in trial participants, which makes it less efficient than traditional COVID-19 injections.
On 6/11/2021 Piper Sandler brokerage Initiated Coverage with Overweight rating and a Price Target of $18.00
From a technical analysis point of view, the stock looks in an uptrend.
A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates.
On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies in trial participants, which makes it less efficient than traditional COVID-19 injections.
On 6/11/2021 Piper Sandler brokerage Initiated Coverage with Overweight rating and a Price Target of $18.00
From a technical analysis point of view, the stock looks in an uptrend.
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.